knowledge -WSS

knowledge

author：Wikipedia 2025-08-23 04:57:59 - browse：919

Micrograph of ulcerative colitis -- biotech coverage from STAT — Micrograph of chronic active ulcerative colitis in a biopsy specimen. Wikimedia Commons

Checkpoint inhibitors, drugs that unleash the immune system, have turned into blockbuster therapies that have transformed outcomes for some patients with deadly cancers. AltruBio, a Bay Area biotech, is betting it can help patients suffering from autoimmune and inflammatory diseases by taking the opposite tack: pumping the brakes on runaway immune responses.

The company on Tuesday announced that it has raised $225 million in a Series B venture round led by BVP Partners, with the biotech’s backers also including RA Capital Management, Cormorant Asset Management, and Soleus Capital. AltruBio plans to put that money toward advancing a drug that is already being tested in a mid-stage trial for ulcerative colitis, an increasingly competitive market in which a number of pharma companies have launched drugs.

It’s the latest example of intense investor interest in immunology-focused companies. Firms such as Paragon Therapeutics and Prometheus Laboratories have recently been at the center of financing mega-rounds, and Blackstone Life Sciences recently committed up to $300 million to launch Uniquity Bio, a company developing treatments for asthma and chronic obstructive pulmonary disease.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Bright Health sells Medicare Advantage business to Molina
Next article： Digital health: a case of mistaken identity

hotspot

entertainment

focus

WSS

Biogen walks away from Aduhelm, years after polarizing approval

Cue Health, Covid

Medicare Advantage insurers face 0.2% cut to 2025 payments

Readout Newsletter: Vertex, Pfizer, Kura, and other biotech news

Syphilis numbers in the United States reach record heights

Reports of telehealth's death have been greatly exaggerated

Wikipedia

knowledge

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

leisure time

DIEP, the 'gold standard' of breast reconstruction, is under threat

H5N1 virus can be tracked in retail milk, scientists say

Virginia high school admissions case could be legal follow

Investment in vaccine development is lagging, report finds

Drug repurposing or repositioning? The language matters

Addressing health care workers' trauma can help fight burnout

Peter Hotez and the public health issue of online harassment

Addressing health care workers' trauma can help fight burnout

As demand for Covid shots wanes, Moderna seeks its next success

For longer

leisure time

H5N1 bird flu outbreak: Second human case reported, in Michigan

Readout Newsletter: H5N1 bird flu vaccine, Cytokinetics, Gilead

Why Medicare shouldn’t cover every FDA

The Readout: Biogen, Guardant, AstraZeneca, H5N1 vaccine

Merck, Johnson & Johnson CEOs will testify on high drug prices

Pancreatic cancer early detection could be helped by AI

hotspot

entertainment

focus

hotspot